Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Lymphoma, Non-Hodgkin × Sofosbuvir × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Liver Diseases 1 Hepatitis C, Chronic 1 Hepatitis C 1 Carcinoma, Hepatocellular 1

Interventions

Rituximab 5 Cyclophosphamide 3 pegfilgrastim 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Drug Therapy 2 plerixafor 1 pirtobrutinib 1 ledipasvir, sofosbuvir drug combination 1 ibrutinib 1 ibritumomab tiuxetan 1 fludarabine phosphate 1 entecavir 1 Vincristine 1 Valsartan 1 Thiotepa 1 Tenofovir 1 Sofosbuvir 1 Ribavirin 1 Radiotherapy 1 Prilocaine 1 Prednisone 1 Oxygen 1 Ifosfamide 1 Fibroblast Growth Factor 7 1 Doxorubicin 1 Dexamethasone 1 Cytarabine 1 Ciprofloxacin 1 Ceftazidime 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡